Completed PHASE2 INTERVENTIONAL 1-arm NCT00799604

Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT) (SPRINT)

An Open-label Study in Patients Undergoing Cardiac Surgery to Evaluate the Effect of Bolus Clevidipine Administration (SPRINT)

Sponsor: The Medicines Company

Conditions Hypertension

Interventions clevidipine

Updated 8 times since 2017 Last updated: Aug 21, 2014 Started: Nov 30, 2008 Primary completion: Oct 31, 2009 Completion: Oct 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00799604, this PHASE2 trial focuses on Hypertension and remains completed. Sponsored by The Medicines Company, it has been updated 8 times since 2008, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Medicines Company

Data source: The Medicines Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States
• Philadelphia, United States